一分钟看懂
这是一项关于急性髓系白血病的早期 I 期研究，登记的药物或干预包括GT737 Injection，当前状态为尚未开始招募。登记地点显示中国深圳有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
GT737 Injection · 早期 I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Shenzhen People's Hospital · 深圳
公开的入选条件
- * 1\. Voluntarily participate in this clinical study, fully understand the study content, sign the informed consent form, and be willing to comply with all study procedures and complete all follow-up visits.
- * 2\. Aged between 18 and 75 years old (inclusive), with no restriction on gender.
- * 3\. Confirmed diagnosis of relapsed/refractory acute myeloid leukemia (AML) per the 2016 WHO Classification, with the specific definitions as follows:
- Confirmed AML with bone marrow blasts ≥5% at screening, and meeting any one of the following criteria:
- * Relapsed disease: Relapse after achieving complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) following standard induction chemotherapy;
- * Refractory disease: a) Failure to achieve CR/CRi after 2 cycles of induction chemotherapy; b) Relapse within 12 months of first remission with no response to subsequent re-treatment; c) Relapse after autologous or allogeneic hematopoietic stem cell transplan
- 4\. Confirmed positive expression of CD33 or CD70 via flow cytometry and/or immunohistochemistry.
- 5\. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07676006；登记信息更新于 2026-09-11。